52 Results for "

Ige Inhibitors

" in MedChemExpress (MCE) Product Catalog:
Products (52)

52 Results for "Ige Inhibitors" in MCE Product Catalog:

7
7 Publications Verification
Cat. No.: HY-N0631
CAS No.: 131189-57-6
Cornuside is an iridoid glycoside with anti-allergic, anti-inflammatory, and neuroprotective activities. Cornuside exerts anti-allergic activity by downregulating the p38 MAPK, JNK, and NF-κB signaling pathways, and inhibits IgE-mediated histamine release from mast cells. Cornuside improves cognitive impairment in mice by inhibiting BACE1 activity (IC50 = 55.84 μg/mL) and enhancing ChAT activity. Cornuside inhibits LPS (HY-D1056)-induced inflammatory mediators, including iNOS, COX-2, PGE2, TNF-α, IL-6, and IL-1β, by suppressing NF-κB activation .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-A0059
CAS No.: 4936-47-4
Synonyms: NF 113; SAP 113; Methylmercadone
Nifuratel (NF 113) is an orally active broad-spectrum antibiotic with antiprotozoal, antibacterial, anticancer and anti-inflammatory activities, and has good inhibitory effects on Candida and Trichomonas. Nifuratel is also a STAT3 inhibitor, which significantly inhibits the growth and proliferation of human gastric cancer cells and induces apoptosis. In addition, Nifuratel also inhibits mast cell-mediated antigen hypersensitivity reactions and can be used in the study of IgE-mediated allergic diseases .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-114495
CAS No.: 21802-37-9
Purity:  ≥98.0%
Synonyms: Cerulomycin; Caerulomycin
Caerulomycin A is an orally active immunomodulator and antimicrobial agent. Caerulomycin A targets Smad3, STAT1 and GATA-3. Caerulomycin A downregulates GATA-3 expression, inhibits Th2 cell differentiation and Th2 cytokine production, reduces IgE levels, and alleviates pulmonary inflammatory responses and eosinophil infiltration. Caerulomycin A ameliorates collagen-induced arthritis symptoms, reduces joint inflammation and synovitis, and decreases the levels of proinflammatory cytokines in joints. Caerulomycin A inhibits the growth of some filamentous fungi, yeasts and specific bacteria. Caerulomycin A can be used in research related to arthritis and asthma .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P99300
CAS No.: 1322627-61-1
Synonyms: QGE 031; Anti-IGHE Recombinant Antibody

Target:  

Fc Receptor (FcR)

Research Areas:  

Inflammation/Immunology

Ligelizumab (QGE 031) is a humanized high-affinity anti-immunoglobulin IgE monoclonal antibody. Ligelizumab selectively inhibits the binding of IgE to the high-affinity receptor FcεRI, while the inhibitory effect on the low-affinity receptor CD23 is weak. Ligelizumab can inhibit the activation of effector cells such as mast cells and Basophil, while reducing the production of IgE by B cells, and restoring the IFN-α production and regulatory T cell (Treg) induction function of plasmacytoid dendritic cells (pDC). Ligelizumab can be used in the study of allergic diseases (such as chronic spontaneous urticaria, allergic asthma) .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-17002
CAS No.: 94055-76-2
Synonyms: IPD 1151T
Target:  

Interleukin Related

Research Areas:  

Inflammation/Immunology

Suplatast Tosilate (IPD 1151T) is an orally active Th2 cytokine inhibitor which can inhibit both IL-4 and IL-5 production from Th2 cells and suppress IgE synthesis. Suplatast Tosilate is an anti-allergic agent. Suplatast Tosilate has antiasthmatic, anti-inflammatory and antifibrotic activity .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-139690
CAS No.: 2615910-00-2
Purity:  98.96%
CCG258747 is a selective GRK2 inhibitor (IC50 = 18 nM) with high selectivity over GRK1, GRK5, PKA, and ROCK1 (518, 83, > 5500, and > 550-fold, respectively). CCG258747 also blocks the internalization of the µ-opioid receptor (MOR). CCG258747 attenuates IgE mediated anaphylaxis by inhibiting GRK2 and FcεRI signaling pathway but activates mast cells via MRGPRX2 and MRGPRB2. CCG258747 can be used to study diseases related to overexpression of GRK2 (such as heart failure, opioid tolerance) .
loading...
    loading...
Cat. No.: HY-P990774
CAS No.: 2768386-15-6
Synonyms: ASP-7266; TRAB-1; UPB-101

Target:  

Interleukin Related

Research Areas:  

Inflammation/Immunology

Verekitug (ASP-7266; TRAB-1; UPB-101) is a human monoclonal antibody targeting the thymic stromal lymphopoietin receptor (TSLPR), with a mean half-life of approximately 20 days. At doses of Verekitug ≥100 mg, complete and sustained TSLPR-specific occupancy is achieved, and the antibody does not bind to IL-7Rα. By inhibiting TSLP-driven inflammatory responses, Verekitug blocks TSLP-induced cell proliferation and TARC expression, while reducing fractional exhaled NO levels, blood eosinophil counts, and levels of IL-5 and IgE. Verekitug significantly improves scores for nasal polyps, nasal congestion and olfactory dysfunction, with favorable safety and good tolerability; potential adverse reactions include headache, upper respiratory tract infection, sinusitis and nasopharyngitis. Verekitug is used in relevant studies on asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease .
loading...
    loading...
Cat. No.: HY-P991636

Research Areas:  

Inflammation/Immunology

AK006 is a humanized IgG1 monoclonal antibody agonist targeting Sialic acid-binding immunoglobulin-like lectin6 (Siglec-6). AK006 potently inhibits IgE-mediated human mast cell activation. AK006 can be used for inflammatory diseases like chronic urticaria (CU) and asthma research .
loading...
    loading...
Cat. No.: HY-P99371
CAS No.: 2283348-97-8
Synonyms: AK002; Antolimab

Target:  

Apoptosis

Research Areas:  

Inflammation/Immunology

Lirentelimab (AK002) is a humanized IgG1 monoclonal antibody that targets sialic acid-binding Ig-like lectin 8 (SIGLEC8). Lirentelimab induces cell apoptosis of IL-5-activated eosinophils and inhibits IgE-mediated mast cell activation. Lirentelimab can be used for the research of eosinophilic gastritis and duodenitis .
loading...
    loading...
Cat. No.: HY-16420
CAS No.: 575474-82-7
Target:  

Syk

Research Areas:  

Inflammation/Immunology

R112 is a fast and reversible inhibitor of spleen tyrosine kinase (Syk) kinase. R112 inhibits Syk kinase activity with an IC50 value of 226 nM and a Ki value of 96 nM. R112 inhibits IgE-FcεRI signaling pathway. R112 can be used for the research of allergic rhinitis .
loading...
    loading...
Cat. No.: HY-43521
CAS No.: 1710768-30-1
Ibrutinib-MPEA is an orally active, blood-brain barrier permeable inhibitor of BTK and STAT5. As a derivative of Ibrutinib (HY-10997) conjugated with a PROTAC linker, Ibrutinib-MPEA allows the synthesis of a series of PROTAC molecules. Ibrutinib-MPEA significantly reduces the proliferation of neoplastic mast cells and primary mastocytoma cells by inducing apoptosis and inhibiting IgE-dependent histamine release. Ibrutinib-MPEA is applicable to the research of canine mast cell tumors, cerebral ischemia/reperfusion injury in diabetic mice, and neuroinflammation-related diseases .
loading...
    loading...
Cat. No.: HY-B0426A
CAS No.: 140462-76-6
Synonyms: ALO4943A; KW4679
Olopatadine hydrochloride (ALO4943A; KW4679) is an orally active histamine H1 receptor antagonist and mast cell stabilizer. Olopatadine hydrochloride exerts antiallergic effects by blocking histamine H1 receptor-mediated activities. Olopatadine hydrochloride inhibits exocytosis, chemokine release, F-actin polymerization, CXCL10-induced calcium influx, and T cell chemotactic activity. Olopatadine hydrochloride also reduces the expression levels of CXCR3 on the surface of CD4 + and CD8 + T cells. Olopatadine hydrochloride inhibits scratching behavior, improves dermatitis scores, and suppresses intraepidermal neurite outgrowth. Olopatadine hydrochloride simultaneously decreases the levels of inflammatory markers, growth factors, histamine, and specific IgE, while increasing the expression of ErbB3A/HER3A. Olopatadine hydrochloride can be used in research related to seasonal pollinosis, chronic rhinitis, urticaria, allergic conjunctivitis, alopecia areata, and atopic dermatitis .
loading...
    loading...
Cat. No.: HY-W062109
CAS No.: 113806-05-6
Olopatadine (ALO4943A; KW4679) is an orally active histamine H1 receptor antagonist and mast cell stabilizer. Olopatadine exerts antiallergic effects by blocking histamine H1 receptor-mediated activities. Olopatadine inhibits exocytosis, chemokine release, F-actin polymerization, CXCL10-induced calcium influx, and T cell chemotactic activity. Olopatadine also reduces the expression levels of CXCR3 on the surface of CD4 + and CD8 + T cells. Olopatadine inhibits scratching behavior, improves dermatitis scores, and suppresses intraepidermal neurite outgrowth. Olopatadine simultaneously decreases the levels of inflammatory markers, growth factors, histamine, and specific IgE, while increasing the expression of ErbB3A/HER3A. Olopatadine can be used in research related to seasonal pollinosis, chronic rhinitis, urticaria, allergic conjunctivitis, alopecia areata, and atopic dermatitis .
loading...
    loading...
Cat. No.: HY-P1130
CAS No.: 908844-75-7
Synonyms: Galanin-(2-13)-Glu-His-(Pro)3-(Ala-Leu)2-Ala-amide
M871 (Galanin-(2-13)-Glu-His-(Pro)3-(Ala-Leu)2-Ala-amide) is an orally active and selective galanin receptor type 2 (GalR2) antagonist. M871 exhibits Ki values of 13.1 nM, 420 nM and >10 μM for GalR2, GalR1 and GalR3 respectively. M871 relieves the mice allergic rhinitis by reducing IgE production, as well as the number of B cells in tissues. M871 can inhibit the nerve invasion of salivary adenoid cystic carcinoma (SACC) and alleviate myocardial ischemia-reperfusion injury. M871 can be used for research on GalR2-related diseases (such as epilepsy, pain) .
loading...
    loading...
Cat. No.: HY-174903
CAS No.: 2616666-32-9
Target:  

Itk

Research Areas:  

Inflammation/Immunology

ITK-IN-6 is a highly potent and selective ITK inhibitor (Kd = 387 nM). ITK-IN-6 directly binds to the ITK kinase domain. ITK-IN-6 blocks the release of pro-inflammatory cytokines and the activation and differentiation of Th2 and Th17 cells. ITK-IN-6 improves asthma progression by reducing inflammatory cell infiltration, mucus and IgE production. ITK-IN-6 significantly inhibits airway inflammation and is used in asthma research .
loading...
    loading...
Cat. No.: HY-113512
CAS No.: 90780-52-2
Purity:  98.8%
17-HDHA is a DHA-derived specialized pro-resolving mediator (SPM). 17-HDHA inhibits NF-κB activation by activating PPARγ and upregulating IκBα, targets FPR2 and Bcl-6, and also acts as a precursor of RvD1 and PD1. 17-HDHA inhibits pulmonary artery smooth muscle cell proliferation, regulates the expression of adiponectin, GLUT-4 and inflammatory cytokines, suppresses IgE production by B cells and promotes antibody secretion. 17-HDHA reduces adipose tissue inflammation, improves insulin sensitivity and glucose tolerance, alleviates pathological processes associated with pulmonary hypertension, and enhances antibody responses and virus neutralizing activity against influenza HA. 17-HDHA can be used in research related to obesity-associated inflammation, insulin resistance, glucose intolerance, pulmonary hypertension and influenza virus infection .
loading...
    loading...
Cat. No.: HY-124146
CAS No.: 1319738-39-0
Target:  

Syk

Research Areas:  

Inflammation/Immunology

BI1002494 is an orally active, potent, and selective spleen tyrosine kinase (SYK) inhibitor. BI 1002494 exhibits an IC50 of 115 nM in inhibiting high-affinity IgE receptor-mediated mast cell and basophil degranulation. BI1002494 can be utilized in immunology reesearch .
loading...
    loading...
Cat. No.: HY-13218
CAS No.: 114607-46-4
Purity:  98.70%
Synonyms: WP-871
Target:  

Histamine Receptor

Research Areas:  

Inflammation/Immunology

Acitazanolast is an orally active antiallergic agent, can inhibit histamine release. Acitazanolast can be used in study of type I anaphylaxis (immediate) caused by IgE antibodies .
loading...
    loading...
Cat. No.: HY-W062109S
CAS No.: 1231979-85-3
Olopatadine-d6 is the deuterium labeled Olopatadine. Olopatadine hydrochloride (ALO4943A; KW4679) is an orally active histamine H1 receptor antagonist and mast cell stabilizer. Olopatadine hydrochloride exerts antiallergic effects by blocking histamine H1 receptor-mediated activities. Olopatadine hydrochloride inhibits exocytosis, chemokine release, F-actin polymerization, CXCL10-induced calcium influx, and T cell chemotactic activity. Olopatadine hydrochloride also reduces the expression levels of CXCR3 on the surface of CD4 + and CD8 + T cells. Olopatadine hydrochloride inhibits scratching behavior, improves dermatitis scores, and suppresses intraepidermal neurite outgrowth. Olopatadine hydrochloride simultaneously decreases the levels of inflammatory markers, growth factors, histamine, and specific IgE, while increasing the expression of ErbB3A/HER3A. Olopatadine hydrochloride can be used in research related to seasonal pollinosis, chronic rhinitis, urticaria, allergic conjunctivitis, alopecia areata, and atopic dermatitis .
loading...
    loading...
Cat. No.: HY-P991592
CAS No.: 2755114-30-6

Target:  

Inhibitory Antibodies

Research Areas:  

Inflammation/Immunology

UB-221 is a humanized IgG1 monoclonal antibody inhibitor targeting IgE. UB-221 significantly decreases IgE synthesis by stabilization of membrane-bound CD23 on B lymphocytes and inhibits FcԑRI-mediated basophil activation and degranulation. UB-221 reduces IgE level in cynomolgus macaques and human IgE (ε, κ)-transgenic (hIGHE-knockin) mice. UB-221 can be used for asthma and chronic spontaneous urticaria (CSU) research .
loading...
    loading...